DGFT implements fully ban on hydroxychloroquine export from India

  • Posted on: 6 April 2020
  • By: PharmaTutor News

Pharma Admission

Pharma courses

pharma courses

 

Directorate General of Foreign Trade (DGFT) implements fully ban on export of hydroxychloroquine from India. DGFT made export ban from SEZs/EOUs too. Government has made amendment in export Policy of Hydroxychloroquine and its formulation from last amendment which was made on 25th march 2020.

DGFT notified that the export of Hydroxychloroquine and formulations made from Hydroxychloroquine falling under any ITCHS Code, including the ITCHS Codes mentioned in the Notification No. 54 dated 25.3.2020 is no longer allowed from SEZs/EOUs or against Advance Authorisation or under the Para 1.05(b) of Foreign Trade Policy 2015-20 or against full advance payment as specified in Para 2 of the Notification. The export of Hydroxychloroquine and formulations made from Hydroxychloroquine, therefore, shall remain prohibited, without any exception.

Earlier, export was allowed from SEZ / EOU unites and in cases where export is made to fulfill export obligation under any advance license issued on or before 25th March 2020. But in a notification dated 4th April, 2020 DGFT notified such units to stop export without any exemption.

Hydroxychloroquine is antimalarial medicine which known to have effect in COVID-19 infection and it is also recommended by ICMR with proper guidelines for COVID-19. This extreme measures are taken to reduce possibilities of shortage of hydroxychloroquine.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email


 

Latest News